Slingshot members are tracking this event:

Top-Line Data Expected in Q4 2017 for Aimmune's (AIMT) Phase 3 PALISADE Trial Evaluating AR101 in Peanut Allergies

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data Update on June 20 2017: preliminary data presented.
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Palisade, Top-line Data, Peanut Allergies